Natalie Holles
About Natalie Holles
Natalie Holles is a Director at Day One Biopharmaceuticals, where she has worked since 2021. With over 20 years of experience in executive leadership and business development, she has held various significant roles in the biopharmaceutical industry, including positions at Audentes Therapeutics and Genentech.
Work at Day One Biopharmaceuticals
Natalie Holles has been serving as Director at Day One Biopharmaceuticals since 2021. In this role, she contributes to the strategic direction and operational management of the company. Her extensive background in the biopharmaceutical industry supports her efforts in driving the company's initiatives forward.
Education and Expertise
Natalie Holles holds a Master of Arts in Molecular, Cellular, and Developmental Biology from the University of Colorado Boulder. She also earned an A.B. in Human Biology from Stanford University. Her educational background provides a strong foundation for her expertise in the biopharmaceutical sector, particularly in executive leadership, business development, and corporate strategy.
Background
Natalie Holles has over 20 years of experience in executive leadership and business development within the biopharmaceutical industry. She has held various roles including Director at Allakos Inc and Rubius Therapeutics, as well as leadership positions at Audentes Therapeutics, where she served as President and CEO. Her career includes significant contributions to corporate development and commercial strategies at companies like Genentech and InterMune.
Achievements
Throughout her career, Natalie Holles has held several key leadership positions, including Vice President of Business Development at KAI Pharmaceuticals and Senior Vice President at Hyperion Therapeutics. She was also a Howard Hughes Medical Institute predoctoral fellow. Her roles have involved providing strategic advisory services to biopharmaceutical companies, showcasing her influence in the industry.